The speakers emphasize that symptom burden can alter sequencing priorities and prompt greater integration of supportive interventions alongside tumor directed therapy. Regular symptom assessment and ...
Dr. Kimberly Perez and Dr. Jaydira Del Rivero discuss the new guideline from ASCO on symptom management for well-differentiated GEP-NETs. They share the latest recommendations on managing symptoms ...
MIAMI, FLORIDA (April 30, 2024) – Newly updated guidelines on neuroendocrine tumors developed by an expert at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine ...
Cabozantinib significantly delayed disease progression in advanced pancreatic and extra-pancreatic neuroendocrine tumors, as shown in the phase 3 CABINET trial. The trial demonstrated a median PFS of ...
Based on the phase 3 CABINET trial, the FDA approved Cabometyx for some patients with previously treated neuroendocrine tumors. The U.S. Food and Drug Administration (FDA) has approved Cabometyx ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results